Modulating Th17 Cells in IDH1-Mutant Glioma to Promote Antitumor Immunity
Abstract
Gliomas are the most common primary malignant brain tumor of the central nervous system with several studies reporting a higher incidence of disease among military personnel. In its most aggressive form, glioblastoma (GBM), patients are met with a dismal median survival of approximately 15 months and usually endure a grueling standard of care therapy in the form of radio-chemotherapy. The burgeoning field of immunotherapy holds great promise for patients and families afflicted by brain tumors with much progress being made in understanding how mutations in brain tumors impact the tumor-immune microenvironment to promote or suppress immune activity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2021
- Accession Number
- AD1152646
Entities
People
- Christopher J. Pirozzi
Organizations
- Duke University